Brief: MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 In Combination With Bevacizumab In Relapsed Metastatic Colorectal Cancer Patients
11/04/2024 15:38
April 11 (Reuters) - MEI Pharma Inc MEIP.O :
* MEI PHARMA REPORTS INITIAL DATA FROM CLINICAL STUDY
EVALUATING
ME-344 IN COMBINATION WITH BEVACIZUMAB (AVASTIN®) IN RELAPSED
METASTATIC COLORECTAL CANCER PATIENTS
* MEI PHARMA INC: ME-344 IN COMBINATION WITH BEVACIZUMAB WAS
GENERALLY WELL-TOLERATED WITH NO EVIDENCE OF OVERLAPPING
TOXICITY
Source text for Eikon: ID:nBw3vNHYta
Further company coverage: MEIP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lite Strategy
See all newsBrief: Lite Strategy Receives Governance Rights And Option To Buy Litvm Future Network Tokens
U.S. RESEARCH ROUNDUP- Equinix, KLA, WW Grainger
Brief: Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing
Brief: Lite Strategy Reports First Quarter Fiscal Year 2026 Results Highlights Successful Launch Of $100M Litecoin Treasury Strategy And Movement Into Active Capital Market Operations
Brief: Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation To Active Capital Market Operations